Back

Antiplatelet drugs: clinically relevant details on the pharmacology of P2Y12 inhibitors - discussion

26 August 2023 (11:55 - 12:00)
Organised by: Logo
Congress Presentation Part of: Pharma Made Easy Pharmacology and Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

5 More presentations in this session

Presentation thumbnail
Lipid lowering agents: how to make optimal use of the full spectrum
Professor F. Mach (Geneva, CH)
Slides
Presentation thumbnail
Lipid lowering agents: how to make optimal use of the full spectrum - discussion
Presentation thumbnail
GLP-1 agonists: how do they work?
Professor U. Laufs (Leipzig, DE)
Slides
Presentation thumbnail
GLP-1 agonists: how do they work? - discussion
Presentation thumbnail
Antiplatelet drugs: clinically relevant details on the pharmacology of P2Y12 inhibitors
Professor S. Massberg (Munich, DE)
Slides

Access the full session

Session thumbnail
Pharma Made Easy

The Event

Event poster

ESC Congress 2023

26 August 2023 11:55 CET
You may be interested in
thumbnail
Congress Presentation
Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients
1 September 2019
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
6 July 2023
thumbnail
Congress Presentation
Panel discussion - PANTHER.
29 August 2022
thumbnail
Congress Presentation
Choice of P2Y12 inhibitor and clinical outcomes in the AUGUSTUS study: support for an individualised approach
30 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources